Estimaciones de analistas de Wall Street para Relmada Therapeutics, Inc. (RLMD): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-12 | $-0.14 | ||
| 2026-08-06 | $-0.11 | $-0.20 | +44.9% |
| 2026-05-12 | $-0.22 | $-0.18 | -22.2% |
| 2026-03-19 | $-0.27 | $-0.14 | -92.9% |
| 2025-11-13 | $-0.30 | $-0.04 | -650.0% |
| 2025-08-07 | $-0.30 | $-0.25 | -20.0% |
| 2025-05-12 | $-0.58 | $-0.31 | -87.1% |
| 2025-03-27 | $-0.62 | $-0.70 | +11.4% |
Ratios de valoración
| Precio / Valor contable | 2.14 |
| EV / EBITDA | -6.71 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2017 | 2018 | 2019 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | $85271 | $2627 | $4870 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Bruto | -$85271 | -$2627 | -$4870 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| I+D | $1.3M | $2.9M | $7.0M | $7.9M | $36.0M | $90.6M | $113.3M | $54.8M | $46.2M | $744560 |
| Generales y Administrativos | $5.7M | $4.0M | $5.7M | $7.2M | $24.9M | $35.1M | $47.9M | $48.9M | $37.7M | $311904 |
| Gastos Operativos | $7.2M | $6.9M | $12.7M | $15.1M | $60.8M | $125.7M | $161.2M | $103.7M | $83.9M | $59.1M |
| Beneficio Operativo | -$7.2M | -$6.9M | -$12.7M | -$15.1M | -$60.8M | -$125.7M | -$161.2M | -$103.7M | -$83.9M | -$59.1M |
| EBITDA | -$6.9M | -$6.9M | -$16.6M | -$15.1M | -$59.3M | -$125.8M | -$157.0M | $4.9M | -$80.0M | -$57.4M |
| Gastos por Intereses | $550 | $1.3M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$6.3M | -$9.0M | -$17.3M | -$15.0M | -$59.5M | -$125.8M | -$157.0M | -$98.8M | -$80.0M | -$57.4M |
| Impuestos | 0 | 0 | $4.6M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$6.3M | -$9.0M | -$17.3M | -$15.0M | -$59.5M | -$125.8M | -$157.0M | -$98.8M | -$80.0M | -$57.4M |
| BPA | $-2.08 | $-2.86 | $-2.74 | $-1.63 | $-3.81 | $-7.16 | $-5.30 | $-3.28 | $-2.65 | $-1.45 |
| BPA Diluido | $-2.08 | $-2.86 | $-2.74 | $-1.63 | $-3.81 | $-7.16 | $-5.30 | $-3.28 | $-2.65 | $-1.45 |
| Acciones en Circulación (Diluidas) | $3.0M | $3.1M | $6.3M | $9.2M | $15.6M | $17.6M | $29.6M | $30.1M | $30.2M | $39.5M |
Precio
| Precio | $4.22 |
| Capitalización | $443M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ACET · ACRV · CBUS · FBIO · IMUX · LITS · PMVP
Explorar sector: Healthcare · Biotechnology
Más secciones de RLMD: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones